the market?
Hemispherx BioPharma, Inc.
NYSEMKT: HEB
0.20
0.00
(-1.25%)
| Today's Open | $0.20 |
|---|---|
| Previous Close | $0.20 |
| Daily Range | $0.20 - $0.21 |
| 52-Week Range | $0.18 - $1.10 |
| Market Cap | $33.1M |
| P/E Ratio | -1.68 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 331,239 |
| Average Daily Volume | 342,461 |
| Current FY EPS | $0.00 |
How do you think HEB
will perform against the market?
Top HEB Bull/Bear Pitches
zzlangerhans (< 20)
Submitted
August 25, 2010
Hemispheryx puts me in mind of a novel called Perfume, by Patrick Susskind. The protagonist is a murderer who lies dormant for years, likened to a tick on a branch, simply awaiting the passage of a wa … More
Allstar13913 (< 20)
Submitted
February 22, 2007
Bill Mann said it best. This stock is crap. Ampligen their
News & Commentary
Hemispherx's Unsurprising 45% Plunge
Hemispherx shares are down 45% after the release of a damning FDA briefing document.UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Hemispherx
Hemispherx's Chronic Fatigue Drug Rejected by FDA
The agency says Ampligen needs additional testing to show that it works and is safe. The company says it will appeal the decision and implores hunger striker to start eating.Four Closely Watched Drug Decisions Loom in February
The month also features a big gathering of biotech CEOs in New York and a cancer research meeting in Florida.5 High-Profile Drugs Expect FDA Decisions in February
The month also features a big gathering of biotech CEOs in New York and a cancer research meeting in Florida.Hemispherx Chronic Fatigue Drug Scrutinized Ahead of Panel Review
Shares of the drug maker are falling after FDA staff questioned whether the drug Ampligen works. The stock previously was on a tear, running up 200% in 2012 on hope for US approval of the treatment.Sector
Healthcare
Industry
Drugs
Hemispherx BioPharma, Inc. (HEB) Description
A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Website: http://www.hemispherx.net/
